Status:
UNKNOWN
Long-Term Effect of LIAM on Respiratory Performance in NIV Patients Suffering From Neuromuscular Disease
Lead Sponsor:
Centre d'Investigation Clinique et Technologique 805
Conditions:
Neuromuscular Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The long-term effect of LIAM (Lung Insufflation Assist Maneuver) on respiratory performance in home non-invasively ventilated (NIV) patients suffering from neuromuscular disease will be assessed in a ...
Detailed Description
In advanced neuromuscular disorders, respiratory complications represent the main cause of morbidity and mortality. Beside chronic respiratory insufficiency, necessitating a ventilatory support, mostl...
Eligibility Criteria
Inclusion
- o neuromuscular disease ( progressive muscular dystrophy, for example; Duchenne muscular dystrophy, spinal muscular atrophy)
- age ≥ 18 years
- indication to NIV (ongoing ventilation or new patients)
- vital capacity ≤ 50% pred
- peak cough flow \< 270 l/min
- "LIAM Responder" = increased insufflation capacity (≥ + 50%) and Peak Cough Flow (PCF ≥+ 50%) with LIAM
Exclusion
- o acute respiratory failure (respiratory acidosis)
- home treatment by instrumental cough assistance in the preceding 12 months
- ongoing medical treatment of the neuromuscular disease (for ex: corticosteroids in Duchenne disease, enzyme therapy in Pompe disease)
- previous pneumothorax
- plan of legal protection
- pregnant or breastfeeding women
- failure to cooperate
- no affiliation to a social security scheme
Key Trial Info
Start Date :
October 29 2015
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2021
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT02288299
Start Date
October 29 2015
End Date
December 31 2021
Last Update
November 18 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Home ventilation Unit , Raymond Poincaré hospital
Garches, Paris Area, France, 92380